Menopause isn’t optional: How payers can support women’s health with evidence and education

Executive summary

Menopause is a pivotal life stage with significant implications for healthcare costs, chronic disease risk and quality of life—yet it remains underrepresented in population health strategies. For payers, shifting the focus of menopause from symptom management to population health strategy allows for:

• Proactive risk monitoring
• Evidence-based support to reduce avoidable utilization
• Improvement of quality metrics and long-term member outcomes
• Access to treatments, strategies, and support from payors and clinicians

By integrating Labcorp’s robust diagnostic capabilities and Ovia Health by Labcorp’s personalized engagement platform, health plans can move beyond reactive symptom management to a life cycle–based model that supports women through one of the most consequential health transitions of their lives.

The strategic case: Why menopause matters to payer performance

Menopause affects every woman, yet the healthcare industry often treats it as a sporadic, episodic, and symptom-driven condition rather than a predictable life transition with measurable population health and economic impacts. As clinical guidance evolves and stigmas fade, payers have an opportunity to modernize their approach. 

Data-driven engagement combined with objective clinical insight helps distinguish menopause-related symptoms from other conditions, enables appropriate routing of care and monitors emerging risks that drive long-term costs. This approach is appealing across multiple payer priorities, including: 

• Medical cost containment
• Member experience
• Quality performance
• Long-term risk management

Ignoring menopause is expensive. Population‑level data highlights that women experiencing untreated or poorly managed symptoms have:

• 121% higher healthcare resource utilization
• 57% more lost workdays
• Over $2,100 per year in additional combined medical and absenteeism-related costs 

Further data reveals significant financial exposure resulting from the traditional approach. Research comparing women with and without diagnosed menopause symptoms shows dramatic differences: 

• Medical expenses increase from $2,972 to $4,315 annually (particularly pharmacy costs)
• Productivity losses measured through sick leave grow by 8%

Additionally, nearly 20% of working women have considered leaving employment due to untreated menopause symptoms, representing lost tax revenue for employers and potential coverage disruption for payers. When these factors combine with higher rates of chronic disease development during this time frame, the downstream costs multiply. 

For plans focused on value-based arrangements and risk adjustment, the menopause transition presents both challenge and opportunity. Strategic testing can allow for early recognition and proactive management during this transition and can prevent costly complications while improving quality measure performance across multiple domains.

Moving beyond symptoms: The role of strategic testing in menopause

Menopause is not diagnosed by a single test. Instead, various objective biomarkers play a critical role in differentiating menopause from other conditions with overlapping symptoms by:

• Confirming transition timing for appropriate treatment
• Informing personalized treatment decisions
• Establishing baseline risk profiles for longitudinal monitoring

For payers, strategic testing and access to structured, high‑quality lab data:

• Reduces misdiagnosis rates
• Prevents unnecessary specialist referrals and utilization
• Enables risk-stratified care management
• Drives timely interventions

Rather than viewing testing as a catalog of individual markers, plans can leverage targeted diagnostics that support core functions.

1. Thyroid function: Managing clinical overlap

Thyroid dysfunction often presents with overlapping menopause symptoms such as fatigue, mood changes, weight fluctuations, and cognitive concerns. A simple thyroid stimulating hormone (TSH) assessment helps clinicians differentiate between these conditions early, preventing treatment delays, and reducing the likelihood of multiple provider visits or unnecessary endocrinology referrals. 

For payers, this represents straightforward preventive value, as one appropriately timed test can eliminate diagnostic ambiguity and drive members to effective treatment quicker.

2. Monitoring emerging risks accelerated by the menopause transition

Declining estrogen during menopause influences bone density loss, lipid profiles, insulin sensitivity, and inflammatory markers. Fracture risk and cardiometabolic disease—two major cost drivers—intensify during this period. 

Strategic use of tools such as a metabolic panels and lipid testing allows health plans to identify members trending toward higher-risk categories. For payers managing cardiovascular risk, diabetes, and fracture risk, incorporating menopause-specific protocols enables earlier identification, intervention, and more precise care management resource allocation to prevent high‑cost events later.

3. Hormone assessment for diagnostic clarity

Appropriately timed, hormone-related assessments, including follicle-stimulating hormone (FSH) and broader endocrine panels, can help determine whether symptoms are consistent with ovarian aging or driven by other conditions. This reduces inappropriate specialist referrals, cascading diagnostic workups, and repeat visits.

These testing strategies shouldn't function as stand-alone interventions but rather as components of an integrated care pathway. This approach moves beyond test ordering to strategic risk identification and management that helps reduce avoidable utilization, as women frequently cycle through primary care, behavioral health, urgent care, and multiple specialists before menopause is identified as the underlying and primary driver of symptoms.

Evidence and context on evolving hormone therapy guidance

Recent FDA label updates to many estrogen-containing therapies reflect alignment between current evidence and regulatory language—not a wholesale removal of risk. The FDA's revisions show accumulated evidence about timing, formulation differences, and risk stratification, particularly for women under 60 initiating therapy or for those within 10 years of menopause onset. 

This provides clinicians with more nuanced guidance for more individualized treatment discussions and shared decision-making rather than broad population-level avoidance. These regulatory refinements don't represent a wholesale policy reversal but rather recognition that earlier population-level concerns about hormone therapy were based on studies involving older women using formulations that differed from current options. 

For payers, this translates to more members pursuing evidence-aligned treatment under appropriate clinical supervision, potentially reducing the downstream complications associated with unmanaged menopause symptoms.

Supporting members with personalized insights, symptom tracking, education, and timely care 

Labcorp’s extensive population-level datasets reinforce that physiological changes during midlife are measurable, meaningful, and actionable, creating a strong foundation for targeted risk stratification. This clinical testing provides objective data, but member engagement determines whether that information translates into improved outcomes.

Women often manage menopause alone due to stigma, uncertainty, or concerns about discrimination. This silence delays care and compounds cost. 

Digital tools with symptom tracking, pattern recognition, and personalized education help members understand their health changes and navigate treatment options effectively. Ovia Health by Labcorp's menopause program exemplifies this integrated approach. 

Members track symptoms like sleep disturbances, vasomotor symptoms, and mood changes while receiving personalized educational content matched to their experience. Board-certified health coaches:

• Help members interpret symptoms
• Provide accessible, stigma-free clinical guidance
• Normalize conversations via evidence-based resources
• Assist in evaluating treatment effectiveness
• Understand when provider consultation is warranted and connect women to primary care, behavioral health, and specialist support as needed 

Ovia Health’s combination of personalized technology, self-directed tracking, and human clinical expertise equips members with the knowledge and support they need to get appropriate care. This includes:

• Personalized symptom tracking to help members identify patterns, evaluate trigger-response relationships, and assess whether treatment plans are working
• Proactive outreach from board‑certified clinicians when symptom patterns indicate potential risks
• Adaptive educational content tailored to each user’s stage, clinical history, and reported symptoms

When these tools integrate with diagnostic capabilities and pharmacy benefit management, they allow for coordinated menopause support across the care continuum. This fusion of technology and human support allows payers to engage members earlier and more consistently, long before high-cost events occur.

Menopause represents a significant but often overlooked opportunity for payers to reduce costs, improve quality of life, and manage long-term risk. 

Implementation considerations for payers

Integrating menopause support into population health strategy requires coordination across clinical, pharmacy, and member engagement functions. Key components include:

• Risk stratification protocols that identify members entering or in menopause transition and flag elevated risk factors requiring proactive management
• Care pathway integration connecting symptoms, diagnostic insights, and treatment options through streamlined workflows
• Provider education and support so network physicians have current clinical guidance and access to specialist consultation when needed
• Member communication strategies that normalize menopause conversations and clearly articulate available resources
• Quality measurement alignment incorporating menopause-related interventions into HEDIS®, CMS Stars, and other performance frameworks where applicable